1. Home
  2. EYPT vs BFS Comparison

EYPT vs BFS Comparison

Compare EYPT & BFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EYPT
  • BFS
  • Stock Information
  • Founded
  • EYPT 1987
  • BFS 1993
  • Country
  • EYPT United States
  • BFS United States
  • Employees
  • EYPT N/A
  • BFS N/A
  • Industry
  • EYPT Biotechnology: Laboratory Analytical Instruments
  • BFS Real Estate Investment Trusts
  • Sector
  • EYPT Industrials
  • BFS Real Estate
  • Exchange
  • EYPT Nasdaq
  • BFS Nasdaq
  • Market Cap
  • EYPT 741.0M
  • BFS 779.0M
  • IPO Year
  • EYPT 2005
  • BFS 1993
  • Fundamental
  • Price
  • EYPT $11.09
  • BFS $32.64
  • Analyst Decision
  • EYPT Strong Buy
  • BFS Strong Buy
  • Analyst Count
  • EYPT 7
  • BFS 1
  • Target Price
  • EYPT $24.29
  • BFS $45.50
  • AVG Volume (30 Days)
  • EYPT 643.4K
  • BFS 60.6K
  • Earning Date
  • EYPT 08-06-2025
  • BFS 08-07-2025
  • Dividend Yield
  • EYPT N/A
  • BFS 7.23%
  • EPS Growth
  • EYPT N/A
  • BFS N/A
  • EPS
  • EYPT N/A
  • BFS 1.32
  • Revenue
  • EYPT $51,898,000.00
  • BFS $277,902,000.00
  • Revenue This Year
  • EYPT N/A
  • BFS $10.48
  • Revenue Next Year
  • EYPT N/A
  • BFS $6.52
  • P/E Ratio
  • EYPT N/A
  • BFS $24.74
  • Revenue Growth
  • EYPT 2.99
  • BFS 5.23
  • 52 Week Low
  • EYPT $3.91
  • BFS $31.25
  • 52 Week High
  • EYPT $13.99
  • BFS $42.39
  • Technical
  • Relative Strength Index (RSI)
  • EYPT 61.85
  • BFS 45.14
  • Support Level
  • EYPT $10.22
  • BFS $32.23
  • Resistance Level
  • EYPT $11.28
  • BFS $33.34
  • Average True Range (ATR)
  • EYPT 0.71
  • BFS 0.53
  • MACD
  • EYPT 0.04
  • BFS 0.09
  • Stochastic Oscillator
  • EYPT 89.89
  • BFS 60.45

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

About BFS Saul Centers Inc.

Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.

Share on Social Networks: